Most cited papers from Highlands Oncology Group

Highlands Oncology Group

What are the most cited papers from Highlands Oncology Group?

The most cited paper from Highlands Oncology Group is "Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer" (José Baselga et al., 2011), with 2,868 citations. Next come "Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer" (876) and "Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years" (656).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 32 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer José Baselga et al. · New England Journal of Medicine Open access	7 Dec 2011	2,868
2	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Dennis J. Slamon et al. · New England Journal of Medicine Open access	11 Dec 2019	876
3	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Paul Edward Goss, James N. Ingle, Kathleen I. Pritchard et al. · New England Journal of Medicine Open access	5 Jun 2016	656
4	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology	12 Feb 2013	647
5	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Mary Lenora Disis, Matthew Hiram Taylor, Karen L. Kelly et al. · JAMA Oncology Open access	24 Jan 2019	437
6	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer Sunil R. Hingorani, William Proctor Harris, Joseph Thaddeus Beck et al. · Clinical Cancer Research Open access	26 Jan 2016	330
7	Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer Adam Brufsky, W. Graydon Harker, Joseph Thaddeus Beck et al. · Journal of Clinical Oncology Open access	12 Dec 2006	321
8	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Annals of Oncology Open access	5 Jun 2021	291
9	Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial Hope S. Rugo, Lasika C. Seneviratne, Joseph Thaddeus Beck et al. · The Lancet Oncology	14 Mar 2017	230
10	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial Élisabeth Quoix et al. · The Lancet Oncology	22 Dec 2015	213
11	Final 5‐year results of Z‐FAST trial Adam Brufsky, W. Graydon Harker, Joseph Thaddeus Beck et al. · Cancer	10 Oct 2011	192
12	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4) Miguel Martín, A. Chan, Luc Yves Dirix et al. · Annals of Oncology Open access	24 Oct 2016	186
13	Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial J.M. Weiss et al. · Annals of Oncology Open access	22 Aug 2019	174
14	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer Ralph Zinner, Coleman K. Obasaju, David Robert Spigel et al. · Journal of Thoracic Oncology Open access	5 Nov 2014	173
15	A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events Swaminathan P. Iyer, Joseph Taddeus Beck, A. Keith Stewart et al. · British Journal of Haematology Open access	19 Aug 2014	157
16	Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center Joseph Thaddeus Beck, Melissa Rammage, Gretchen Purcell Jackson et al. · JCO Clinical Cancer Informatics	24 Jan 2020	133
17	Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study Giuseppe Curigliano, Patricia Gómez Pardo, Funda Meric‐Bernstam et al. · The Breast Open access	20 Jun 2016	132
18	Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study Lowell L. Hart, Renata Ferrarotto, Zoran Gojko Andric et al. · Advances in Therapy Open access	29 Oct 2020	125
19	Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma Joseph Thaddeus Beck, Amen Ismail, Christina Tolomeo · Cancer Treatment Reviews	3 Jul 2014	119
20	Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study Carlo B Gambacorti-Passerini, Sergey Orlov, Li Zhang et al. · American Journal of Hematology Open access	20 Jan 2018	114
21	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke et al. · Breast Cancer Research and Treatment Open access	21 Nov 2017	113
22	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors Timothy Anthony Yap, Aditya Bardia, Michael Dvorkin et al. · JAMA Oncology Open access	17 Nov 2022	109
23	Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC Jennifer Jane Knox, Carlos H. Barrios, T.M. Kim et al. · Annals of Oncology Open access	21 Feb 2017	107
24	Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial Howard A. Burris, Fabienne Lebrun, Hope S. Rugo et al. · Cancer Open access	15 Mar 2013	102
25	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer Howard A. Burris, Arlene Chan, Aditya Bardia et al. · British Journal of Cancer Open access	22 Jun 2021	94
26	A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer George R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon et al. · Annals of Oncology Open access	15 Feb 2011	92
27	Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study Hope S. Rugo, Peter Kabos, Julia Beck et al. · npj Breast Cancer Open access	5 Nov 2022	91
28	Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 Joseph Thaddeus Beck, Gabriel N. Hortobágyi, Mario Campone et al. · Breast Cancer Research and Treatment Open access	20 Dec 2013	88
29	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Patrick Neven, PA Fasching, Stephen Chia et al. · Breast Cancer Research Open access	31 Aug 2023	83
30	Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer Mark A. Socinski, Charles Weissman, Lowell L. Hart et al. · Journal of Clinical Oncology	18 Oct 2006	82
31	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) Timothy Francis Cloughesy et al. · Neuro-Oncology Open access	7 Dec 2019	75
32	An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC) Mark Magdi Awad, Q.S-C. Chu, Leena Gandhi et al. · Lung Cancer	30 Dec 2016	64
33	Barriers to dental care for children with autism spectrum disorder S. Barry, E.A. O’Sullivan, Kyriacos Jack Toumba · European Archives of Paediatric Dentistry	13 Aug 2013	60
34	A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer Vera A. Gorbunova, Joseph Thaddeus Beck, Ralf‐Dieter Hofheinz et al. · British Journal of Cancer Open access	5 Dec 2018	58
35	Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer Joyce O’Shaughnessy, Joseph Thaddeus Beck, Melanie Royce · Cancer Treatment Reviews Open access	23 Jul 2018	57
36	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer Sherko Kuemmel et al. · Clinical Cancer Research Open access	6 Oct 2021	54
37	Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Annals of Oncology Open access	Oct 2019	54
38	First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial Wolfgang Janni, Emilio Alba, Thomas Bachelot et al. · Breast Cancer Research and Treatment	5 Feb 2018	52
39	Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato et al. · The Lancet Haematology	23 Feb 2021	50
40	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors Jordi A. Rodon, Giuseppe Curigliano, Jean‐Pierre Delord et al. · Oncotarget Open access	3 Aug 2018	50
41	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen Anthony H. Kong, Daniel William Rea, Samreen I. Ahmed et al. · Oncotarget Open access	25 Apr 2016	49
42	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors Gregory Lawrence Beatty, Safi Shahda, Thaddeus Beck et al. · The Oncologist Open access	16 Aug 2018	47
43	Severe Histoplasmosis in Travelers to Nicaragua Michelle S. Weinberg, Julia Weeks, Susan E. Lance-Parker et al. · Emerging infectious diseases Open access	Oct 2003	46
44	Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study Komal L. Jhaveri et al. · Journal of Clinical Oncology Open access	6 Sep 2024	45
45	Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study Jennifer Keating Litton, Joseph Thaddeus Beck, Jason Michael Jones et al. · The Oncologist Open access	15 Jun 2023	45
46	Planting Date, Cultivar, and Tillage System Effects on Dryland Soybean Production Michael P. Popp, T. C. Keisling, Ronald W. McNew et al. · Agronomy Journal	2002	44
47	Inkblot Perception and Personality: The Holtzman Inkblot Technique Raymond J. McCall, Wayne H. Holtzman, Joseph S. Thorpe et al. · The American Journal of Psychology	Dec 1964	44
48	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer Lauren A. Byers, Alejandro Navarro, Eric Scott Schaefer et al. · Clinical Lung Cancer Open access	24 Apr 2021	42
49	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression Nikhil C. Munshi, Rafat Abonour, Joseph Thaddeus Beck et al. · Blood	16 Nov 2012	40
50	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study Peter Andreas Fasching, Joseph Thaddeus Beck, Arlene Chan et al. · The Breast Open access	23 Sep 2020	38

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.